Approval · Notice of Compliance 36006 · 2025
VYVANSE: Notice of Compliance 36006
Issued September 15, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36006
- Date
- September 15, 2025
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph with new safety information. Product Monograph reformatted to the Master Template
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VYVANSE | Not yet assigned | — |
Medicinal ingredients
- LISDEXAMFETAMINE DIMESYLATE 10 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 20 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 30 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 40 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 50 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 60 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 70 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 10 MG per TAB
- LISDEXAMFETAMINE DIMESYLATE 20 MG per TAB
- LISDEXAMFETAMINE DIMESYLATE 30 MG per TAB
- LISDEXAMFETAMINE DIMESYLATE 40 MG per TAB
- LISDEXAMFETAMINE DIMESYLATE 50 MG per TAB
- LISDEXAMFETAMINE DIMESYLATE 60 MG per TAB